Evercore ISI raised the firm’s price target on Arvinas (ARVN) to $19 from $14 and keeps an Outperform rating on the shares. Arvinas is “gearing up for a pivotal 2026,” says the analyst, who adds that the company’s recent call highlighted progress on their strategic pivot with significant data readouts expected across multiple programs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas price target raised to $20 from $16 at Piper Sandler
- Arvinas: Strong Pipeline Momentum, De-Risked Cash Runway, and Attractive Risk‑Reward Support Buy Rating
- Arvinas Earnings Call: High Science, Tight Cash
- Balancing Emerging Clinical Momentum and Commercial Uncertainty: Maintaining a Hold on Arvinas Ahead of Key 2026 Readouts
- Arvinas price target raised to $11 from $9 at Wedbush